Cargando…
SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS: A retrospective, observation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493113/ https://www.ncbi.nlm.nih.gov/pubmed/28680862 http://dx.doi.org/10.1186/s40200-017-0308-4 |
_version_ | 1783247447579951104 |
---|---|
author | Tamez-Perez, Héctor Eloy Delgadillo-Esteban, Enrique Soni-Duque, David Hernández-Coria, Mayra Ivonne Tamez-Peña, Alejandra Lorena |
author_facet | Tamez-Perez, Héctor Eloy Delgadillo-Esteban, Enrique Soni-Duque, David Hernández-Coria, Mayra Ivonne Tamez-Peña, Alejandra Lorena |
author_sort | Tamez-Perez, Héctor Eloy |
collection | PubMed |
description | BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes. Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals were established as <7%. RESULTS: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of patients was 57.68 ± 11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19.44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, P < 0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was associated with better control (P < 0.05, 95% CI, [1.10, 3.92]). CONCLUSION: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as combined therapy. |
format | Online Article Text |
id | pubmed-5493113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54931132017-07-05 SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study Tamez-Perez, Héctor Eloy Delgadillo-Esteban, Enrique Soni-Duque, David Hernández-Coria, Mayra Ivonne Tamez-Peña, Alejandra Lorena J Diabetes Metab Disord Research Article BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes. Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals were established as <7%. RESULTS: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of patients was 57.68 ± 11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19.44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, P < 0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was associated with better control (P < 0.05, 95% CI, [1.10, 3.92]). CONCLUSION: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as combined therapy. BioMed Central 2017-06-30 /pmc/articles/PMC5493113/ /pubmed/28680862 http://dx.doi.org/10.1186/s40200-017-0308-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Tamez-Perez, Héctor Eloy Delgadillo-Esteban, Enrique Soni-Duque, David Hernández-Coria, Mayra Ivonne Tamez-Peña, Alejandra Lorena SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
title | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
title_full | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
title_fullStr | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
title_full_unstemmed | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
title_short | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
title_sort | sglt2 inhibitors as add on therapy in type 2 diabetes: a real world study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493113/ https://www.ncbi.nlm.nih.gov/pubmed/28680862 http://dx.doi.org/10.1186/s40200-017-0308-4 |
work_keys_str_mv | AT tamezperezhectoreloy sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT delgadilloestebanenrique sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT soniduquedavid sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT hernandezcoriamayraivonne sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT tamezpenaalejandralorena sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy |